- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Cashew oral immunotherapy desensitizes food allergy symptoms, study finds
Israel: In a new study published in the journal Allergy, it was found that cashew oral immunotherapy (OIT) desensitizes the majority of cashew-allergic patients and cross-desensitizes them to pistachio.
Oral immunotherapy is a therapeutic option for people who are allergic to milk, eggs, or peanuts, although research on the efficacy and safety of cashew OIT is lacking. As a result, Arnon Elizur and colleagues undertook this study to assess the efficacy of cashew OIT in reducing allergy symptoms.
A group of 50 cashew-allergic individuals aged 4 years or more who were recruited in cashew OIT (target dosage 4000 mg protein) from 4/2016 to 12/2019. Fifteen cashew-allergic individuals who continued to avoid cashews acted as controls. It was discovered that the patient had a pistachio and walnut allergy. Both groups' full desensitization rates and accompanying immunological alterations were studied. Patients who had become completely desensitized to cashew were directed to ingest a dosage of 1200 mg cashew protein for 6 months before being exposed to the maximum amount. Patients with co-allergies to pistachio or walnut were exposed to the nut in question.
The results of this study stated as follow:
1. At the end of the research, 44 of 50 OIT-treated patients (88%) tolerated a dosage of 4000 mg cashew protein, compared to 0% of controls.
2. 3 more patients were desensitized to 1200 mg cashew protein, and three patients discontinued therapy.
3. For home responses, three patients (6%) received injectable epinephrine.
4. Following therapy, desensitized individuals showed lower SPT, sIgE, basophil reactivity, and higher sIgG4.
5. All pistachio (n = 35) and four of eight walnut co-allergic patients were cross-desensitized to the corresponding nut after cashew desensitization.
6. Following desensitization, all (n = 44) patients who consumed a low cashew dosage for 6 months passed a full-dose cashew OFC.
In conclusion, the findings of this study points out the efficiency of OIT in desensitization of cashew allergy and it can also be followed safely with other food allergy OIT treatment.
Reference:
Elizur, A, Appel, MY, Nachshon, L, et al. Cashew oral immunotherapy for desensitizing cashew-pistachio allergy (NUT CRACKER study). Allergy. 2022; 00: 1– 10. doi:10.1111/all.15212
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751